Cargando…

Circulating Melanoma Cells: Scoping the Target

Detalles Bibliográficos
Autores principales:	Joshi, Powrnima, Zborowski, Maciej, Triozzi, Pierre L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2013
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3740478/ https://www.ncbi.nlm.nih.gov/pubmed/23964346 http://dx.doi.org/10.3389/fonc.2013.00189

Ejemplares similares

Enrichment of circulating melanoma cells (CMCs) using negative selection from patients with metastatic melanoma
por: Joshi, Powrnima, et al.
Publicado: (2014)

Multiparameter Evaluation of the Heterogeneity of Circulating Tumor Cells Using Integrated RNA In Situ Hybridization and Immunocytochemical Analysis
por: Wu, Yongqi, et al.
Publicado: (2016)

Circulating MicroRNAs as Quantitative Biomarkers for Diagnosis and Prognosis of Uveal Melanoma
por: Zhou, Wen-Da, et al.
Publicado: (2022)

Effects of Epithelial to Mesenchymal Transition on T Cell Targeting of Melanoma Cells
por: Woods, Katherine, et al.
Publicado: (2014)

Targeting Myelogenous Leukemia Stem Cells: Role of the Circulation
por: Liesveld, Jane
Publicado: (2012)

Adhesion receptors as therapeutic targets for circulating tumor cells
por: Li, Jiahe, et al.
Publicado: (2012)

Rolling in the deep: therapeutic targeting of circulating tumor cells
por: King, Michael R.
Publicado: (2012)

Cornering metastases: therapeutic targeting of circulating tumor cells and stem cells
por: Faltas, Bishoy
Publicado: (2012)

Case Report: Dynamic overlap of melanoma, sarcoidosis, and targeted therapy for BRAF-mutant melanoma
por: Dar, Nakul, et al.
Publicado: (2023)

Neuropilin-1 as Therapeutic Target for Malignant Melanoma
por: Graziani, Grazia, et al.
Publicado: (2015)

Mucosal Melanoma: Pathological Evolution, Pathway Dependency and Targeted Therapy
por: Ma, Yanni, et al.
Publicado: (2021)

Anchored Multiplex PCR Custom Melanoma Next Generation Sequencing Panel for Analysis of Circulating Tumor DNA
por: Diefenbach, Russell J., et al.
Publicado: (2022)

Targeted Therapy; From Advanced Melanoma to the Adjuvant Setting
por: Ahn, Antonio, et al.
Publicado: (2013)

Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets
por: Basile, Maria Sofia, et al.
Publicado: (2019)

MicroRNA Signature in Melanoma: Biomarkers and Therapeutic Targets
por: Ghafouri-Fard, Soudeh, et al.
Publicado: (2021)

Survival and Failure Outcomes Predicted by Brain Metastasis Volumetric Kinetics in Melanoma Patients Following Upfront Treatment with Stereotactic Radiosurgery Alone
por: LeCompte, Michael C, et al.
Publicado: (2017)

Circulating Tumor DNA Testing Supports Rapid Therapeutic Decision-Making in Metastatic Melanoma: A Case Report
por: Behera, Tapas Ranjan, et al.
Publicado: (2022)

Bacterial Cyclodipeptides Target Signal Pathways Involved in Malignant Melanoma
por: Durán-Maldonado, Mayra Xóchitl, et al.
Publicado: (2020)

Editorial: Mechanisms of resistance to the targeted therapy and immunotherapy in cutaneous melanoma
por: Premi, Sanjay, et al.
Publicado: (2022)

MiRNA-128-3p Restrains Malignant Melanoma Cell Malignancy by Targeting NTRK3
por: Zhou, Xinxin, et al.
Publicado: (2021)

Circulating Tumor Cells for Glioma
por: Zhang, Huikai, et al.
Publicado: (2021)

A Targeted Gene Panel for Circulating Tumor DNA Sequencing in Neuroblastoma
por: Cimmino, Flora, et al.
Publicado: (2020)

Advances in Personalized Targeted Treatment of Metastatic Melanoma and Non-Invasive Tumor Monitoring
por: Klinac, Dragana, et al.
Publicado: (2013)

CXC Chemokines as Therapeutic Targets and Prognostic Biomarkers in Skin Cutaneous Melanoma Microenvironment
por: Zhou, Xuezhi, et al.
Publicado: (2021)

Therapeutic Advancements Across Clinical Stages in Melanoma, With a Focus on Targeted Immunotherapy
por: Trojaniello, Claudia, et al.
Publicado: (2021)

YY1 Is a Key Player in Melanoma Immunotherapy/Targeted Treatment Resistance
por: Kwiatkowska, Dominika, et al.
Publicado: (2022)

Case report: Real-world experience using a personalized cancer-specific circulating tumor DNA assay in different metastatic melanoma scenarios
por: Khaddour, Karam, et al.
Publicado: (2022)

Membrane Hsp70—A Novel Target for the Isolation of Circulating Tumor Cells After Epithelial-to-Mesenchymal Transition
por: Breuninger, Stephanie, et al.
Publicado: (2018)

Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup Study
por: Marconcini, Riccardo, et al.
Publicado: (2022)

Circulating Tumor Cells: Back to the Future
por: Gallerani, Giulia, et al.
Publicado: (2017)

Mitochondria dysfunction in circulating tumor cells
por: Agnoletto, Chiara, et al.
Publicado: (2022)

Molecular, Biological and Structural Features of V(L) CDR-1 Rb44 Peptide, Which Targets the Microtubule Network in Melanoma Cells
por: Girola, Natalia, et al.
Publicado: (2019)

Clinical Application of Circulating Tumor Cells and Circulating Endothelial Cells in Predicting Bladder Cancer Prognosis and Neoadjuvant Chemosensitivity
por: Yang, Xiao, et al.
Publicado: (2022)

Clinical Applications of Circulating Tumour Cells and Circulating Tumour DNA in Non-Small Cell Lung Cancer—An Update
por: Kapeleris, Joanna, et al.
Publicado: (2022)

Discoidin Domain Receptors in Melanoma: Potential Therapeutic Targets to Overcome MAPK Inhibitor Resistance
por: Reger de Moura, Coralie, et al.
Publicado: (2020)

A Model of Dendritic Cell Therapy for Melanoma
por: DePillis, Lisette, et al.
Publicado: (2013)

Poor Lymphocyte Infiltration to Primary Tumors in Acral Lentiginous Melanoma and Mucosal Melanoma Compared to Cutaneous Melanoma
por: Nakamura, Yoshiyuki, et al.
Publicado: (2020)

Targeted Next-Generation Sequencing of Circulating Tumor DNA, Bone Marrow, and Peripheral Blood Mononuclear Cells in Pediatric AML
por: Ruan, Min, et al.
Publicado: (2021)

Genetics of melanoma
por: Wangari-Talbot, Janet, et al.
Publicado: (2013)

The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon
por: Triozzi, Pierre L, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_k6u2hu48vjo41lnq48nuoi69a5